163 related articles for article (PubMed ID: 20497962)
1. Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid.
Terpos E; Christoulas D; Kokkoris P; Anargyrou K; Gavriatopoulou M; Migkou M; Tsionos K; Dimopoulos MA
Ann Oncol; 2010 Jul; 21(7):1561-1562. PubMed ID: 20497962
[No Abstract] [Full Text] [Related]
2. Frail elderly patients with relapsed-refractory multiple myeloma: efficacy and toxicity profile of the combination of bortezomib, high-dose dexamethasone, and low-dose oral cyclophosphamide.
Mele G; Giannotta A; Pinna S; Loseto G; Coppi MR; Brocca CM; Melpignano A; Quarta G
Leuk Lymphoma; 2010 May; 51(5):937-40. PubMed ID: 20350279
[No Abstract] [Full Text] [Related]
3. [Case report; a case of acute kidney injury due to intravenous zoledronic acid hydrate, improved with bortezomib plus dexamethazone therapy in a patient with multiple myeloma].
Koike K; Morishige S; Fukami K; Taguchi K; Yakushiji K; Okamura T; Okuda S
Nihon Naika Gakkai Zasshi; 2011 Jan; 100(1):179-81. PubMed ID: 21387650
[No Abstract] [Full Text] [Related]
4. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
[TBL] [Abstract][Full Text] [Related]
5. Waldeström macroglobulinaemia relapsing with focal bone disease and achieving major response with single-agent zoledronic acid.
Bakhous A; Zhu H; Waheed S
Br J Haematol; 2013 Nov; 163(3):293. PubMed ID: 23930696
[No Abstract] [Full Text] [Related]
6. Bortezomib induced a phrenic palsy in a multiple myeloma patient.
Nizeica V; Collet P; Marotte H
Ann Hematol; 2013 Aug; 92(8):1135-6. PubMed ID: 23370597
[No Abstract] [Full Text] [Related]
7. Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial.
Rodon P; Hulin C; Pegourie B; Tiab M; Anglaret B; Benboubker L; Jardel H; Decaux O; Kolb B; Roussel M; Garderet L; Leleu X; Fitoussi O; Chaleteix C; Casassus P; Lenain P; Royer B; Banos A; Benramdane R; Cony-Makhoul P; Dib M; Fontan J; Stoppa AM; Traullé C; Vilque JP; Pétillon MO; Mathiot C; Dejoie T; Avet-Loiseau H; Moreau P
Haematologica; 2015 Feb; 100(2):e56-9. PubMed ID: 25398832
[No Abstract] [Full Text] [Related]
8. Different dose combinations of bortezomib and dexamethasone in the treatment of relapsed or refractory myeloma: an open-label, observational, multi-center study in China.
Yuan ZG; Jin J; Huang XJ; Li Y; Chen WM; Liu ZG; Chen XQ; Shen ZX; Hou J
Chin Med J (Engl); 2011 Oct; 124(19):2969-74. PubMed ID: 22040537
[TBL] [Abstract][Full Text] [Related]
9. Best treatment strategies in high-risk multiple myeloma: navigating a gray area.
Bianchi G; Richardson PG; Anderson KC
J Clin Oncol; 2014 Jul; 32(20):2125-32. PubMed ID: 24888801
[TBL] [Abstract][Full Text] [Related]
10. Hyperammonemic encephalopathy in multiple myeloma.
Jones FM; Bokhari SW
Ann Hematol; 2014 Aug; 93(8):1431-2. PubMed ID: 24292538
[No Abstract] [Full Text] [Related]
11. A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events.
Iyer SP; Beck JT; Stewart AK; Shah J; Kelly KR; Isaacs R; Bilic S; Sen S; Munshi NC
Br J Haematol; 2014 Nov; 167(3):366-75. PubMed ID: 25139740
[TBL] [Abstract][Full Text] [Related]
12. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies.
Dimopoulos MA; Kastritis E; Christoulas D; Migkou M; Gavriatopoulou M; Gkotzamanidou M; Iakovaki M; Matsouka C; Mparmparoussi D; Roussou M; Efstathiou E; Terpos E
Leukemia; 2010 Oct; 24(10):1769-78. PubMed ID: 20739955
[TBL] [Abstract][Full Text] [Related]
13. Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma.
Dimopoulos MA; Orlowski RZ; Facon T; Sonneveld P; Anderson KC; Beksac M; Benboubker L; Roddie H; Potamianou A; Couturier C; Feng H; Ataman O; van de Velde H; Richardson PG
Haematologica; 2015 Jan; 100(1):100-6. PubMed ID: 25261096
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
[TBL] [Abstract][Full Text] [Related]
15. [Regression of an osteolytic lesion in a patient with multiple myeloma treated with clodronate after a successful therapy with bortezomib-based regimen].
Szturz P; Jakubcová R; Adam Z; Klincová M; Krejcí M; Pour L; Zahradová L; Hájek R; Mayer J
Klin Onkol; 2011; 24(3):216-20. PubMed ID: 21717791
[TBL] [Abstract][Full Text] [Related]
16. Effective salvage treatment of recurrent Ewing sarcoma utilizing chemotherapy and zoledronic acid.
Siddiqui T; Marsh Rde W; Allegra C; Whittaker D; Scarborough M; Gibbs P; Zlotecki R; Reith JD; Drane W
Clin Adv Hematol Oncol; 2010 Jul; 8(7):499-504. PubMed ID: 20864918
[No Abstract] [Full Text] [Related]
17. Bortezomib in combination with dexamethasone for relapsed multiple myeloma.
Kropff MH; Bisping G; Wenning D; Volpert S; Tchinda J; Berdel WE; Kienast J
Leuk Res; 2005 May; 29(5):587-90. PubMed ID: 15755512
[TBL] [Abstract][Full Text] [Related]
18. [Carfilzomib in multiple myeloma relapses].
Bay JO
Bull Cancer; 2015 Feb; 102(2):116. PubMed ID: 25874287
[No Abstract] [Full Text] [Related]
19. Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma.
Schmielau J; Teschendorf C; König M; Schmiegel W; Graeven U
Leuk Lymphoma; 2005 Apr; 46(4):567-9. PubMed ID: 16019485
[TBL] [Abstract][Full Text] [Related]
20. Novel agents for relapsed and/or refractory multiple myeloma.
Thomas SK; Richards TA; Weber DM
Cancer J; 2009; 15(6):485-93. PubMed ID: 20010168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
